GLP-1 Dosing Errors: Telehealth Data

Dosing errors involving GLP-1 compounds are climbing sharply, according to new reporting on the telehealth weight-loss industry — and the pattern has less to do with the drugs themselves than with how doses get measured, communicated, and verified before they reach the end user. For anyone working with semaglutide, tirzepatide, or related research compounds, the underlying story is a unit-and-concentration problem, not a chemistry problem.

What the Data Shows

KFF Health News reported in June 2026 that patients using telehealth-prescribed compounded semaglutide have been hospitalized after receiving doses far outside standard ranges — in one documented case, a starting dose nearly nine times the typical amount. That is not a rounding error; it is the kind of mistake that happens when a prescribed milligram amount, a compounded concentration, and a self-administered injection volume are not clearly reconciled before the product reaches the patient.

The scale of the problem shows up in federal adverse-event data. Reports of GLP-1 medication errors submitted to the FDA’s Adverse Event Reporting System (FAERS) rose from roughly 2,000 in 2020 to more than 25,000 in 2025 — a more than tenfold increase over five years, tracking almost exactly with the explosion in telehealth-based GLP-1 access. The FDA’s own review of these reports found that the most frequent issues were administration of an extra or incorrect dose, unclear product communication, and prescribing errors — not adverse reactions to the compound itself.

Regulators have responded on the marketing side rather than the measurement side. The FDA sent warning letters to more than 30 telehealth companies in September 2025 and again in February 2026, and issued another 25 warning letters during the week of June 15, 2026 — the common thread in nearly all of them being misleading claims about the equivalence of compounded GLP-1 products to their FDA-approved counterparts, not necessarily the dosing process itself. See Sheppard Mullin’s analysis of the warning-letter wave.

Open Questions for Researchers

Several questions remain open as this story develops: Will the FDA’s compounding oversight actions extend beyond marketing claims into concentration-verification standards for compounding pharmacies? Will telehealth platforms start requiring a documented, vial-specific dosing calculation before dispensing, rather than a generic starting-dose recommendation? And will adverse-event reporting improve enough to show whether errors cluster around specific compounding pharmacies, specific diluent practices, or specific patient populations?

All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.